Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 118, Issue 17, Pages -Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.2011574118
Keywords
multiple sclerosis; microRNAs; small noncoding RNAs
Categories
Funding
- Swedish Research Council (Vetenskapsradet)
- Swedish Association for Persons with Neurological Disabilities
- Swedish Brain Foundation
- Swedish MS Foundation
- Stockholm County Council (ALF project)
- AstraZeneca (AstraZeneca-Science for Life Laboratory collaboration)
- European Union's Horizon 2020 research innovation programme [733161]
- European Research Council [818170]
- Knut and Alice Wallenberg Foundation
- Swedish Society for Medical Research
- Science for Life Laboratory
- Swedish National Infrastructure for Computing (SNIC)/Uppsala Multidisciplinary Center for Advanced Computational Science
- H2020 Societal Challenges Programme [733161] Funding Source: H2020 Societal Challenges Programme
- European Research Council (ERC) [818170] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
The study found widespread changes in miRNAs and other sncRNAs in patients with multiple sclerosis, especially more pronounced in CSF cells, showing a striking contrast with changes in peripheral blood cells. This suggests that sncRNA-mediated mechanisms play an important role in regulating the transcriptome of pathogenic cells, primarily in the CNS target organ.
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease affecting the central nervous system (CNS). Small non-coding RNAs (sncRNAs) and, in particular, microRNAs (miRNAs) have frequently been associated with MS. Here, we performed a comprehensive analysis of all classes of sncRNAs in matching samples of peripheral blood mononuclear cells (PBMCs), plasma, cerebrospinal fluid (CSF) cells, and cell-free CSF from relapsing-remitting (RRMS, n = 12 in relapse and n = 11 in remission) patients, secondary progressive (SPMS, n = 6) MS patients, and noninflammatory and inflammatory neurological disease controls (NINDC, n = 11; INDC, n = 5). We show widespread changes in miRNAs and sncRNA-derived fragments of small nuclear, nucleolar, and transfer RNAs. In CSF cells, 133 out of 133 and 115 out of 117 differentially expressed sncRNAs were increased in RRMS relapse compared to remission and RRMS compared to NINDC, respectively. In contrast, 65 out of 67 differentially expressed PBMC sncRNAs were decreased in RRMS compared to NINDC. The striking contrast between the periphery and CNS suggests that sncRNA-mediated mechanisms, including alternative splicing, RNA degradation, and mRNA translation, regulate the transcriptome of pathogenic cells primarily in the CNS target organ.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available